Scaling Proteomics: Balancing Performance and Measuring Enough Proteins
Explore the advancements in proteomics platforms, with a focus on precision, sensitivity and specificity
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains?
To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
Additionally, since most proteins not yet measurable are low-abundance non-secreted proteins, the webinar will address whether credible physiological signals exist in that fraction and if expanding proteomic measurements to encompass the entire proteome is worthwhile.
Stephen Williams, MD, PhD
Chief Medical Officer
Standard BioTools
Stephen Williams, MD, PhD, is the Chief Medical Officer at Standard BioTools and oversees clinical application of the SomaScan® Platform.
Before joining Standard BioTools, Dr. Williams co-founded the pharma consultancy Decisionability, LLC and authored the book Decisionability: The skill to make your decisions productive, practical and painless. Previously, he worked at Pfizer, Inc., initially in experimental medicine and later as the Vice President and Worldwide Head of Clinical Technology. He was also on the National Advisory Council for Biomedical Imaging and Bioengineering at the U.S. National Institutes of Health. He helped launch the Alzheimer’s Disease Neuroimaging (ADNI) study and form the FDA-FNIH-PhRMA biomarker consortium. He led or co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Dr. Williams has degrees in physiology, medicine and surgery, and received his doctorate in medicine and physiology from Charing Cross and Westminster Medical School (now a part of Imperial College, London). He also obtained training in diagnostic imaging at the University of Newcastle Upon Tyne.
Scaling proteomics: Balancing performance and measuring enough proteins
A presentation by Stephen Williams, MD, PhD
More webinars
WebinarRethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is reshaping how we predict, diagnose, and understand neurodegenerative diseases. In this roundtable, leading experts Tony Wyss-Coray, PhD, and Jacob Vogel, PhD, explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. They discuss how protein signatures can reveal brain aging, predict dementia, and track changes in disease pathways over time, with moderation by Steve Williams, MD, PhD. Learn how cutting-edge proteomics is redefining what is possible in neurological research.
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.